KLEO PHARMACEUTICALS INC.

Kleo Pharmaceuticals to Present at Two Upcoming Industry Conferences

Retrieved on: 
Thursday, May 16, 2019
Articles, Health, Life sciences, Pharmacy, Biotechnology, Communication, Forward-looking statement, Pharmaceutical industry, Cancer immunotherapy, Biopharmaceutical

Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.

Key Points: 
  • Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.
  • They are also much faster and less costly to design and produce, particularly against novel targets.
  • This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws.
  • These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management.

Kleo Pharmaceuticals to Present at the 2019 BIO Asia International Conference

Retrieved on: 
Tuesday, February 26, 2019
Articles, Health, Communication, Forward-looking statement, Pharmaceutical industry, Cancer immunotherapy

Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.

Key Points: 
  • Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.
  • They are also much faster and less costly to design and produce, particularly against novel targets.
  • This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws.
  • These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management.

Kleo Pharmaceuticals to Present at 2019 BIO CEO & Investor Conference in New York City

Retrieved on: 
Wednesday, February 6, 2019
Articles, Health, Communication, Forward-looking statement, Pharmaceutical industry, Cancer immunotherapy

Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.

Key Points: 
  • Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.
  • They are also much faster and less costly to design and produce, particularly against novel targets.
  • This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws.
  • These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management.

Kleo Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

Retrieved on: 
Thursday, December 20, 2018
Medicine, Immunology, Health, Biology, Biotechnology, Immune system, Monoclonal antibodies, Cancer immunotherapy, Biopharmaceutical, Antibody

Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.

Key Points: 
  • Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics.
  • They are also much faster and less costly to design and produce, particularly against novel targets.
  • These include Antibody Recruiting Molecules (ARMs), Synthetic Antibody Mimics (SyAMs) and Monoclonal Antibody Therapy Enhancers (MATEs).
  • These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management.